Autres langues Immunovia AB

Actions

IMMNOV

SE0006091997

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:24:51 25/04/2024			Varia. 5j.	Varia. 1 janv.
2 ^SEK	-4,76 %		+11,86 %	+12,87 %

22/04	Immunovia AB annonce les résultats positifs de l'étude de développement d'un modèle pour son test de détection du cancer du pancréas de nouvelle génération	CI
09/04	Immunovia et Proteomedix créent des tests pour la détection du cancer du pancréas	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Invitation to Immunovia's Q1 presentation	23/04
Immunovia announces updated financial calendar	22/04
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test	22/04
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	22/04
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	09/04
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study	09/04
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	09/04
Immunovia announces updated financial calendar	12/03
Immunovia Publishes Full Year Report for 2023	21/02
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Invitation to Immunovia's Q4 presentation	14/02
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs	31/01
Immunovia announces financial calendar for financial year 2024	04/01
Immunovia AB Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members	21/11
Bulletin from the extraordinary general meeting in Immunovia AB	21/11
Immunovia Publishes Interim Report for January-September 2023	09/11
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Immunovia Shares Surge on Discovery Study for New Pancreatic Cancer Test	07/11
Immunovia successfully completes discovery phase of next-generation test development	07/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Immunovia AB

Actions

IMMNOV

SE0006091997

Autres langues

Filtres